Today we look at an upcoming senate report on the Brazilian government’s COVID-19 response, the trial of Egyptian officers in the murder of Italian researcher Giulio Regeni, and more
As debates heat up on various rules and regulations on commuting during the pandemic, Dr. Satyajit Rath talks about the xenophobic nature of the current international restrictions on air travel
In this show, immunologist Prof. Satyajit Rath sheds light on issues of vaccine equity, possibility of mass inoculation, the need for booster shots and more
India’s government had a year to ramp up its health infrastructure. Instead, crucial time was lost in denial, underestimation, political one-upmanship and blame games
Immunologist Dr. Satyajit Rath and Newsclick’s Prabir Purkayastha talk about the Indian government’s decision to extend the interval between doses
An incompetent, vainglorious leadership, combined with the right-wing belief in magical capitalism, has led to the disaster that India is now facing
Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss the politics, economics and technical aspects of the global vaccine scenario in light of Bill Gates’ recent statement on technology transfer
It has been one year since the Narendra Modi government in India imposed a nationwide lockdown in response to the COVID-19 pandemic.
Today we take a look at recent reports of the killing of civilians in the Tigray region, custodial deaths of Indigenous people in Australia, police repression against a protest in Jordan, and the key lessons learned as India marks 1 year of the Covid-19 lockdown
Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.
The recent regulatory clearance given to an indigenous developed vaccine candidate in India is an example of vaccine nationalism at its worst and jettisoning of all the principles of an evidence-based, scientific approach
The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials